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Objective: Parkinson’s disease (PD) may be caused by the interaction of a number of factors,
including genetics, toxins, oxidative stress, mitochondrial abnormalities, and aging. Studies have
shown that consumption of an antioxidant-rich diet may reduce the incidence of neurodegener-
ative diseases. The aim of this study was to evaluate the role of the ﬂavonoid hesperidin in an
animal model of PD induced by 6-hidroxidopamine (6-OHDA).
Methods: Aged mice were treated with hesperidin (50 mg/kg) during 28 d after an intra-
cerebroventricular injection of 6-OHDA. The enzymatic activities of superoxide dismutase, catalase,
glutathione reductase, glutathione peroxidase, and glutathione S-transferase, the levels of gluta-
thione, reactive oxygen species, total reactive antioxidant potential, dopamine and its levels of
metabolites 3,4-dihydroxyphenylacetic acid and homovanillic acid, was analyzed in the striatum.
The behavioral parameters (depressive-like, memory, and locomotor) were measured.
Results: This study demonstrated that hesperidin (50 mg/kg) treatment was effective in preventing
memory impairment in the Morris water maze test, as well as, depressive-like behavior in the tail
suspension test. Hesperidin attenuated the 6-OHDA-induced reduction in glutathione peroxidase
and catalase activity, total reactive antioxidant potential and the dopamine and its metabolite
levels in the striatum of aged mice. 6-OHDA increased reactive oxygen species levels and gluta-
thione reductase activity in the striatum, and these alterations were mitigated by chronic
administration of hesperidin.
Conclusion: This study demonstrated a protective effect of hesperidin on the neurotoxicity induced
by 6-OHDA in aged mice, indicating that it could be useful as a therapy for the treatment of PD.
 2014 Elsevier Inc. All rights reserved.Introduction of deep nuclei that participate in the initiation and execution ofParkinson’s disease (PD) is a neurologic disorder that is
associated with dopamine (DA) depletion in the striatum and
induction of a gradual dysfunction of the basal ganglia in the
central nervous system [1]. The motor symptoms of PD include
resting tremor, bradykinesia (slowed movements), rigidity
(increased muscular tone), postural instability, and gait impair-
ment, and these features are attributable to dopaminergic cell
loss and the resultant dysfunction of the basal ganglia, a clusterselho Nacional de Desen-
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ll rights reserved.movements [2]. Non-motor symptoms, including memory
impairments, impaired olfaction, disordered sleep, and neuro-
psychiatric manifestations (depression, hallucinations, and de-
mentia), become prominent, and these features are probably due
to the spread of pathology beyond the basal ganglia with the
continued involvement of oxidative stress [2,3]. The adminis-
tration of 6-hydroxydopamine (6-OHDA) into the striatum of
mice produces a well-established model of PD. 6-OHDA selec-
tively destroys the dopaminergic nigrostriatal pathway by
inducing oxidative stress, which can lead to the induction of
inﬂammation and ultimately cell death [1,4,5]. The unilateral
intrastriatal injection of 6-OHDA induces pronounced behavioral
alterations and biochemical deﬁcits similar to PD. Additionally,
6-OHDA is a neurotoxin that rapidly undergoes non-enzymatic
oxidation and produces hydrogen peroxide, superoxide, and
hydroxyl radicals [6].
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removing free radicals and maintaining protein thiols in their
appropriate redox state, is an important protective mechanism
for minimizing oxidative stress [7]. Moreover, antioxidant
enzymes, such as glutathione reductase (GR), glutathione-
peroxidase (GPx), glutathione-S-transferse (GST), catalase (CAT)
and superoxide dismutase (SOD), also are important mediators
in the reduction of oxidative stress [8].
A variety of antioxidant compounds, such as ﬂavonoids
derived from natural products, have demonstrated neuro-
protective activity in either in vitro or in vivo models of PD [5,
9–11]. The bioﬂavonoid hesperidin is a speciﬁc ﬂavonoid
glycoside that is frequently found in oranges and lemons [12]. It
has been reported to possess signiﬁcant anti-inﬂammatory,
antiviral, anticancer [13], and antidepressant-like properties
in mice through the modulation of k-opioid and 5-HT1A sero-
toninergic receptors [14,15]. Several previous studies have
demonstrated the antioxidant activity and radical scavenging
properties of hesperidin in neurodegenerative diseases such as
Huntington’s [16], stroke [17], and Alzheimer’s [18]. Further-
more, this compound has an important neuroprotective prop-
erty related to diverse neuronal insults, such as ischemia [13]
and oxidative-induced damage [19], as well as pathology related
to Alzheimer’s [18] and Huntington’s [16] diseases.
Based on the aforementioned evidence, we sought to investi-
gate the effects of oral hesperidin treatment (50 mg/kg) over 28 d
in an in vivo mouse model of PD induced by the injection of
6-OHDA. We investigated the protective effect of hesperidin on
behavior alterations (i.e., depression-like (are utilized to investigate
depression and action of antidepressants to simulate the patho-
physiology of depressive illness using animals models), cognitive,
and locomotor tests), modiﬁcations in antioxidant enzymes (CAT,
GPx, GR, SOD, and GST), as well as levels of reactive oxygen species
(ROS), GSH, and the total reactive antioxidantpotential (TRAP), in
the striatum of mice. Additionally, we evaluated the protective
effects of hesperidin against neurochemical alterations of DA, and
its levels of metabolites 3,4-dihydroxyphenylacetic acid (DOPAC)
and homovanillic acid (HVA) induced by the striatal injection of
6-OHDA in the aged mice.Materials and methods
Animals
Experiments were performed using aged female C57 BL/6 mice (25–35 g,
18 mo old). Animals were maintained at 22C to 25C with free access to waterFig. 1. Schematic representation of the experimental protocol describing the trea
6-hydroxydopamine; TST, tail suspension test.and food, under a 12-h light–dark cycle, with lights on at 0700. All manipulations
were carried out during the light phase of the day. All efforts were made to
minimize animal suffering and to reduce the number of animals used. The pro-
cedures of this study were conducted according to the guidelines of the Com-
mittee on Care and Use of Experimental Animals Resources and with the
approval of Ethical Committee for Animal Use (CEUA protocol # 001/2013) of the
Federal University of Pampa, Brazil.
Experimental design
Mice were randomly assigned to four groups (n ¼ 10 per group): 1) sham/
vehicle; 2) sham/6-OHDA; 3) hesperidin/vehicle, and 4) hesperidin/6-OHDA. The
mice were subjected to stereotaxic surgical injections of 6-OHDA or vehicle.
Seven d after the injections, treatment with oral hesperidin (50 mg/kg) was
initiated for 28 d, and after behavioral testing, mice were sacriﬁced and the
striatum was removed for biochemical assays (Fig. 1). All analyses (behavioral
assessment and biochemical determinations) were performed in a blinded
fashion.
Stereotaxic surgical injection of 6-OHDA
Surgery was performed under anesthesia with 10 mL/kg of 1% ketamine and
0.2% xylazine. 6-OHDA (5 mg in 2 mL of 0.9% NaCl with 0.2 mg/mL ascorbic acid)
was injected slowly (0.5 mL/min) into the right striatum (0.9 mm anterior and
1.8 mm lateral from bregma, 3.0 mm ventral from the dura). After the injection,
the syringe was maintained in the brain for an additional 3 min before it was
slowly retracted. Controls were injected with the vehicle [19]. All reagents were
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Behavioral assessment
Tail suspension test
Antidepressant-like effects were measured using the tail suspension test
(TST) [20], with minor alterations [14]. Each mouse was suspended by its tail
using adhesive tape placed approximately 1 cm from the tip of the tail, and hung
approximately 30 cm above a table. The animals were suspended for a period of
6 min, and the duration of immobility was scoredmanually during the last 4-min
interval of the test (activity in the ﬁrst 2 min was discarded because animals
predominantly try to escape during this period). Mice were considered immobile
only when they hung passively.
Morris water maze task
The Morris water maze task was used to check the memory capacity of the
animals. The test was performed in a circular swimming pool similar to that
described previously [21]. The pool consisted of black painted ﬁberglass, 97 cm in
diameter and 60 cm in height. For the tests, the tank was ﬁlled with water
maintained at 23C þ 2C. The target platform (10  10 cm2) was made of
transparent Plexiglas and was submerged 1 to 1.5 cm beneath the surface of the
water. Starting points for animals were marked on the outside of the pool as
north (N), south (S), east (E), and west (W). Four distant visual cues (55 55 cm2)
were placed on the walls of the water maze room. They were all positioned such
that their the lower edges were situated 30 cm above the upper edge of the water
tank, and in the standard setting, the position of each symbol marked the
midpoint of the perimeter of a quadrant (circle¼NE quadrant, square¼SE
quadrant, cross¼SW quadrant, and diamond¼NW quadrant). The apparatus wastment periods with 6-OHDA and hesperidin. OFT, open ﬁeld test; 6-OHDA,
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to a spatial reference memory version of the water maze by using a previously
described protocol [22]. The training session consisted of 10 consecutive trials
during which the animals were left in the tank facing the wall and then allowed
to swim freely to the submerged platform. The platformwas located in a constant
position (middle of the southwest quadrant), equidistant from the center and the
wall of the pool. If the animal did not ﬁnd the platform during a period of 60 sec,
it was gently guided to the platform. The animal was allowed to remain on the
platform for 10 sec after escaping to it and was then removed from the tank for
20 sec before being placed at the next starting point in the tank. This procedure
was repeated 10 times, with the starting points (the axis of one imaginary
quadrant) varying in a pseudo-randomized manner. The test session was carried
out 24 h later and consisted of a single probe trial wherein the platform was
removed from the pool and each mouse was allowed to swim for 60 sec in the
maze. The time spent in the correct quadrant (i.e., the quadrant in which the
platformwas located on the training session) was recorded and the percentage of
the total time was analyzed.
Open ﬁeld test
To verify the effects of treatments on the locomotor activity, the animals were
submitted individually to a 5-min open ﬁeld test (OFT; Insight model EP 154 C)
24 h after the last treatment of hesperidin. The parameters observed included the
following: Distance (unit: Mm) and velocity (mm/sec) [23].
Cylinder test
We performed the cylinder test for behavioral evaluation at 1, 2, 3, and 4 wk
after 6-OHDA injections. The cylinder test was used to assess the degree of
forepaw asymmetry. Mice were placed in a transparent cylinder (diameter:
20 cm, height: 30 cm) for 3 min, with the number of forepaw contacts to the
cylinder wall counted [23,24]. The score of cylinder test in this study was
calculated as a contralateral bias: [(the number of contacts with the contralateral
limb)  (the number of contacts with the ipsilateral limb)/(the number of total
contacts)  100] .
Tissue preparation
After behavioral tests, mice were sacriﬁced with a barbiturate overdose
(intraperitoneal pentobarbital sodium 150 mg/kg). The striatum was removed
and rapidly homogenized in 50 mM Tris-Cl, pH 7.4. The homogenate was
centrifuged at 2400g for 15min at 4C, and a low-speed supernatant fraction (S1)
was used for assays.
Biochemical determinations
GSH levels
GSH content was determined ﬂuorometrically using ortho-phthalaldehyde
(OPA) as the ﬂuorophore [25]. S1 (100 mL) was incubated with 100 mL of OPA
(0.1% in methanol) and 1.8 mL of 0.1 M phosphate buffer (pH 8.0) for 15 min at
room temperature in the dark. Fluorescence was measured with a ﬂuorescence
spectrophotometer at the excitation wavelength of 350 nm and at the emission
wavelength of 420 nm. GSH levels were expressed as nmol/g of tissue.
ROS levels
To determine ROS levels, S1 (fresh preparation) was diluted (1:10) in 50 mM
Tris-Hcl (pH 7.4) and incubated with 10 mL of 20 ,70-dichloroﬂuorescein diacetate
(DCHF-DA; 1 mM) at 37C for 30 min. ROS levels were determined by a spec-
troﬂuorimetric method using the DCHF-DA assay, as previously described (2005).
The DCHF-DA is enzymatically hydrolyzed by intracellular esterases to form
nonﬂuorescent DCFH, which is then rapidly oxidized to form highly ﬂuorescent
20 ,70-dichloroﬂuorescein (DCF) in the presence of ROS. DCF ﬂuorescence intensity
is proportional to the amount of ROS that is formed. The DCF ﬂuorescence in-
tensity emission was recorded at 520 nm (with 480 nm excitation) 30 min after
the addition of DCHF-DA to the medium. ROS levels were expressed in arbitrary
units.
TRAP
The non-enzymatic antioxidant potential of the striatum was estimated by
the TRAP [26]. The reaction is initiated by adding luminol (5-amino-2,3-dihydro-
1,4-phthalazinedione, 4 mM), an external probe for monitoring radical produc-
tion, as well as AAPH (2,20-azobis–2-methylpropionamidine–dihydrochloride,
10 mM), a free radical source that produces peroxyl radical at a constant rate, in
glycine buffer (0.1 M) pH 8.6 at room temperature, resulting in a steady lumi-
nescence emission (system counts). Chemiluminescence was read in a liquid
scintillation counter (Agilent Care Elipse) as counts/min. The sample addition
decreases the luminescence proportionately to its antioxidant potential. The
luminescence emission was followed for 40 min after the addition of the sample
(100 g of protein) in a TRAP protocol, and the area under the curve (AUC) was
quantiﬁed. In the TAR protocol, results were expressed as the percentage ofradical production (e.g., system counts considered to be 100% of radical
production).
SOD activity
SOD activity was determined in the striatum according to the method pre-
viously described [27]. This method is based on the ability of SOD to inhibit
autoxidation of epinephrine to adrenochrome. Brieﬂy, the supernatant fraction
(20–60 mL) was added to a medium containing glycine buffer (50 mM; pH 10.5)
and epinephrine (1 mM). The kinetic analysis of SOD was started after the
addition of epinephrine, and the color reaction was measured at 480 nm. One
unit of enzyme was deﬁned as the amount of enzyme required to inhibit the rate
of epinephrine autoxidation by 50% at 30C, and results were expressed as units
(U)/mg of protein.
CAT activity
CAT activity in the supernatant (S1) was assayed spectrophotometrically by a
method previously proposed [28], which involves monitoring the disappearance
of H2O2 in the presence of S1 at 240 nm. Enzymatic reaction was initiated by
adding S1 and the substrate H2O2 (0.3 mM) in a medium containing 50 mM
potassium phosphate buffer (pH 7.0). One unit of enzyme was deﬁned as the
amount of enzyme required for monitoring the disappearance of H2O2. The
enzymatic activitywas expressed as U/mg protein (1 U decomposes 1 mmol H2O2/
min at pH 7.0 at 25C).
GR activity
GR activity was determined spectrophotometrically as described previously
[29]. In this assay, glutathione disulﬁde (GSSG) is reduced by GR at the expense of
nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) consumption,
which was followed at 340 nm. GR activity is proportional to NADPH decay. An
aliquot of S1 was added in the system containing 0.15 M potassium phosphate
buffer (pH 7.0), 1.5 mM EDTA, 0.15 Mm NADPH. After the basal reading, the
substrate (GSSG 20 mM) was added. The enzymatic activity was expressed as
nmol NADPHminmg1 protein.
GPx activity
GPx activity in S1 was assayed spectrophotometrically by the method
described previously [30], through the GSH/NADPH/GR system, by the dis-
mutation of H2O2 at 340 nm. S1 was added to the medium containing the GSH/
NADPH/GR system and the enzymatic reaction was initiated by adding H2O2
(4 mM). In this assay, the enzyme activity was indirectly measured by means of
NADPHdecay.H2O2 is reduced andgeneratesGSSG fromGSH. GSSG is regenerated
back toGSH by the GR that is present in the assaymedia, at the expense of NADPH.
The enzymatic activity was expressed as nmol NADPHminmg1 protein.
GST activity
GST activity was assayed through the conjugation of GSH with 1-chloro-2,4-
dinitrobenzene (CDNB), at 340 nm, as previously described [31]. An aliquot of S1
was added to a medium containing 0.1 M potassium phosphate buffer (pH 7.4).
Then, 100 mM CDNB and GSH were added to the medium. CDNB was used
as a substrate. The enzymatic activity was expressed as nmol CDNB con-
jugatedminmg1 protein.
DA, DOPAC, and HVA levels
Striatal tissues were homogenizedwith 300 mL of 200mM ice-cold perchloric
acid containing 10 mM disodium EDTA. After centrifugation (10 000g for 10 min
at 4C), the supernatant was ﬁltered and then injected directly into a high-
performance liquid chromatography system (Shimadzu; Kyoto, Japan) with an
electrochemical detector (ECD; Eicom, Kyoto, Japan). The appendant potential of
the ECD (carbon electrode versus Ag/AgCl reference electrode) was set at 700mV.
The analytical column was a TSKgel Super-ODS (4.6 mm I.D. 9 100 mm; Tosoh,
Tokyo, Japan), and the mobile phase consisted of 0.1 M citrate-sodium acetate
buffer (pH 3.9) containing methanol (18%, v/v), disodium EDTA (4 mg/L), and
sodium octanesulfonate (0.8 mM) [31].
Protein determination
Protein content was measured colorimetrically according to a previously
described method [32,33], and bovine serum albumin (1 mg/mL) was used as the
standard. The standard of bovine serum albumin was pipetted in different con-
centrations (5, 10, 25, 50 and 100 mg/mL).
Statistical analysis
Results were presented as the means  SEM. First, we evaluated the
normality of data using the D’Agostino and Pearson omnibus normality test.
Comparisons between experimental and control groups were performed by
two-way analysis of variance (ANOVA) followed by Newman–Keuls test for
post hoc comparisonwhen appropriate. Main effects of ﬁrst-order interactions
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tween experimental and control groups were performed by one-way
(hesperidin or 6-OHDA ¼ independent variable) or two-way ANOVAs
(6-OHDA  hesperidin ¼ independent variables). A value of P < 0.05 was
considered signiﬁcant. All tests and plotting graphics were executed using the
GraphPad Prism 5 software (San Diego, CA, USA).Results
Behavioral assessment
Depressive-like behavior in the TST
A two-way ANOVA of depressive-like behavior in the
TST revealed a signiﬁcant 6-OHDA  hesperidin interaction
(F1.40 ¼ 10.86; P ¼ 0.002), as well as main effects of hesperidin
(F1.40 ¼ 89.68; P ¼ 0.001) and 6-OHDA (F1.40 ¼ 21.49; P ¼ 0.001).
Post hoc comparisons demonstrated that animals in the 6-
OHDA/vehicle group showed an increase in immobility time
compared with animals in the sham/vehicle group, exhibiting 6-
OHDA-induced depressive-like behavior in the TST. Daily, oral
hesperidin treatment (50 mg/kg) protected against the increased
time spent immobile in the TST caused by 6-OHDA and
demonstrated an antidepressant-like activity on the sham/hes-
peridin group (Fig. 2).
Morris water maze task
The data presented in Figures 3A and 3B show that mice
treated with 6-OHDA did not differ from the sham/vehicle group
during training (F1.40 ¼ 0.75; P ¼ 0.40) in the escape latency for
ﬁnding the platform, based on the training sessions when the
mice were submitted to the spatial reference memory version of
the water maze. The animals from all experimental groups were
able to learn the task, given that their mean escape latencies
improved throughout the training days.
A two-way ANOVA revealed that time quadrant was changed














































Fig. 2. Effect of daily oral hesperidin treatment (50 mg/kg) and the stereotaxic
surgery injection of 6-OHDA on TST in aged mice. Values are mean  SEM (n ¼ 10/
group). P < 0.05 when comparing 6-OHDA/vehicle or sham/hesperidin with sham/
vehicle. yP < 0.05 when comparing 6-OHDA/hesperidin with 6-OHDA/vehicle.
6-OHDA, 6-hydroxydopamine; TST, tail suspension test.P ¼ 0.001), as well as main effects of hesperidin (F1.40 ¼ 16.80;
P ¼ 0.003) and 6-OHDA (F1.40 ¼ 18.60; P ¼ 0.002). Post hoc
comparisons demonstrated that animals in the 6-OHDA/hes-
peredin group showed an increase in the percentage time spent
in the quadrant compared with that of animals in 6-OHDA/
vehicle group. Oral daily administration of hesperidin (50mg/kg)
protected against impairments in water maze test performance
caused by 6-OHDA administration (Fig. 3C).
Locomotor activity in the OFT
A two-way ANOVA revealed that the total distance in OFT was
not changed signiﬁcantly by a 6-OHDA  hesperidin interaction
(F1.40 ¼ 0.77; P ¼ 0.38), nor by main effects of hesperidin
(F1.40¼ 2.78; P¼ 0.10) or 6-OHDA (F1.40¼ 0.14; P¼ 0.70) (data not
shown).
Statistical analysis of the velocity performed in OFT was not
signiﬁcantly altered by a 6-OHDA  hesperidin interaction
(F1.40 ¼ 0.25; P ¼ 0.61) or a main effect of 6-OHDA (F1.40 ¼ 0.92;
P ¼ 0.34), although a main effect of hesperidin was found
(F1.40 ¼ 4.15; P ¼ 0.04) (data not shown). With this test it is
possible to observe that neither 6-OHDA nor hesperidin treat-
ments caused sedative or excitatory effects on the animals.
Cylinder test
The scores of the cylinder test in the hesperidin group were
ameliorated over time at 2, 3, and 4 wk after 6-OHDA injections
(contralateral bias: 35%  5.6%, 31%  4%, and 20%  3%),
compared with those in the control group (contralateral bias:
79%  7%, 65%  5%, and 64%  3%) (data not shown).
Biomarkers of oxidative stress and neurochemical alterations
GSH levels
A two-way ANOVA revealed that striatal GSH levels were
changed signiﬁcantly by 6-OHDA  hesperidin interaction
(F1.40 ¼ 3.22; P ¼ 0.04), as well as by a main effect of hesperidin
(F1.40¼ 6.65; P¼ 0.02) and 6-OHDA (F1.40¼ 11.12; P¼ 0.004). Post
hoc comparisons demonstrated that 6-OHDA signiﬁcantly
decreased the striatal GSH levels. Oral administration of hes-
peridin (50 mg/kg daily) prevented the inhibition of GSH levels
caused by 6-OHDA in striatum (Table 1).
ROS levels
A two-way ANOVA of striatal ROS levels demonstrated a
signiﬁcant 6-OHDA  hesperidin interaction (F1.40 ¼ 5.35;
P ¼ 0.03), including main effects of hesperidin (F1.40 ¼ 6.55;
P ¼ 0.02) and 6-OHDA (F1.40 ¼ 7.47; P ¼ 0.01). Post hoc com-
parisons revealed that 6-OHDA signiﬁcantly increased striatal
ROS levels. Hesperidin treatment (50 mg/kg daily) protected
against the elevated striatal ROS levels induced by injections of
6-OHDA (Table 1).
TRAP
A two-way ANOVA of striatal TRAP demonstrated a signiﬁcant
6-OHDA  hesperidin interaction (F1.40 ¼ 3.45; P ¼ 0.04).
Furthermore, main effects of hesperidin (F1.40¼ 16.34; P¼ 0.005)
and 6-OHDA (F1.40 ¼ 37.10; P ¼ 0.001) were observed. Post hoc
comparisons revealed that 6-OHDA signiﬁcantly decreased
striatal TRAP. Oral administration of hesperidin (50 mg/kg daily)
prevented reductions of TRAP in striatum (Table 1).
SOD activity
A two-way ANOVA of striatal SOD activity demonstrated
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Fig. 3. Effects of daily oral hesperidin treatment (50 mg/kg) on the spatial learning and memory of mice evaluated in the Morris water maze task. Values are mean  SEM
(n ¼ 10/group). Latency, in seconds (sec), for escape to a submerged platform (A) AUC of the latency in seconds (sec) (B) and percent time in the correct quadrant (C). The
probe test session to evaluate the percent time in the correct quadrant was performed 24 h after the training trials. *P < 0.05 when comparing 6-OHDA/vehicle with sham/
vehicle. yP < 0.05 when comparing 6-OHDA/hesperidin with 6-OHDA/vehicle. AUC, area under curve; 6-OHDA, 6-hydroxydopamine.
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sed the striatal SOD activity, but hesperidin treatment
did not protect against the alterations in SOD activity
(Table 2).
CAT activity
A two-way ANOVA of striatal CAT activity demonstrated
a signiﬁcant 6-OHDA  hesperidin interaction (F1.40 ¼ 9,54;
P ¼ 0.004), as well as main effects of hesperidin (F1.40 ¼ 8.91;
P ¼ 0.001) and 6-OHDA (F1.40 ¼ 7.21; P ¼ 0.01) (Table 2). Post hoc
comparisons revealed that 6-OHDA signiﬁcantly inhibited stria-
tal CAT activity. Oral administration of hesperidin at the daily
dose of 50 mg/kg prevented against the inhibition of striatal CAT
activity (Table 2).Table 1
Effect of hesperidin on GSH and ROS levels and TRAP in striatum of mice injected
with 6-OHDA
Groups GSH* ROSy TRAPz
Sham/vehicle 6.2  0.6 12.8  1.3 99.6  2.9
Sham/hesperidin 6.7  0.8 9.0  1.1 108.8  6.0
6-OHDA/vehicle 3.0  0.6x 3s9.2  5.7x 62.4  4.9x
6-OHDA/hesperidin 5.8  0.6jj 19.6  3.2{ 91.2  3.7jj
GSH, glutathione; 6-OHDA, 6-hydroxydopamine; ROS, reactive oxygen species;
TRAP, total reactive antioxidantpotential
Each value expressed as the mean  SD (n ¼ 10 mice/group)
* GSH levels were expressed as mol/g of tissue.
y ROS levels were expressed as arbitrary unit.
z Results were expressed as percentage of radical production.
x P < 0.05 when compared 6-OHDA/vehicle with sham/vehicle.
jj P < 0.05 when compared 6-OHDA/hesperidin with 6-OHDA/vehicle.
{ P < 0.05 when compared 6-OHDA/hesperidin with 6-OHDA/vehicle and
sham/vehicle.GR activity
A two-way ANOVA of striatal GR activity demonstrated
a signiﬁcant 6-OHDA  hesperidin interaction (F1.40 ¼ 28.43;
P ¼ 0.001), including main effects of hesperidin (F1.40 ¼ 28.57;
P ¼ 0.001) and 6-OHDA (F1.40 ¼ 12.35; P ¼ 0.002). Post hoc
comparisons revealed that 6-OHDA signiﬁcantly increased the
striatal GR activity, and the daily administration of hesperidin
(50 mg/kg) prevented against the increase of GR activity caused
by 6-OHDA (Table 2).
GPx activity
A two-way ANOVA demonstrated that GPx activity in the
striatum revealed a signiﬁcant 6-OHDA  hesperidin interaction
(F1.40 ¼ 8.47; P ¼ 0.01), as well as main effects of hesperidin
(F1.40 ¼ 13.73; P ¼ 0.001) and 6-OHDA (F1.40 ¼ 10.08; P ¼ 0.005)
(Table 2). Post hoc comparisons demonstrated that 6-OHDA
signiﬁcantly inhibited striatal GPx activity. Oral administration
of hesperidin (50 mg/kg daily) prevented the 6-OHDA-induced
inhibition of GPx activity.
GST activity
A two-way ANOVA of striatal GST levels did not show a sig-
niﬁcant 6-OHDA hesperidin interaction (F1.40¼ 0.03; P¼ 0.85),
nor main effects of hesperidin (F1.40 ¼ 0.95; P ¼ 0.33) or 6-OHDA
(F1.40 ¼ 0.38; P ¼ 0.53).
DA, DOPAC, and HVA levels
The statistical analysis of striatal DA levels revealed a signif-
icant 6-OHDA  hesperidin interaction (F1.40 ¼ 6.57; P ¼ 0.02),
including main effects of 6-OHDA (F1.40 ¼ 84.64; P ¼ 0.001) and
hesperidin (F1.40 ¼ 4.86; P ¼ 0.04). Post hoc comparisons
Table 2
Effect of hesperidin on SOD, CAT, GR, GPx and GST Activities in striatum of mice injected with 6-OHDA
Groups SOD* CATy GRz GPxx GSTjj
Sham/vehicle 6.0  0.4 0.25  0.04 47.7  2.78 44.9  2.1 21.6  4.7
Sham/hesperidin 7.5  0.6 0.27  0.02 54.4  2.26 47.5  3.8 19.6  1.5
6-OHDA/vehicle 9.2  1.8{ 0.10  0.02{ 76.6  2.31{ 25.3  1.6{ 23.6  1.6
6-OHDA/hesperidin 10.2  0.6{ 0.22  0.02# 43.9  2.55** 46.9  4.3** 20.7  1.2
CAT, catalase; CDNB, 1-chloro-2,4-dinitrobenzene; GPx, glutathione peroxidase; GR, glutathione reductase; GST, glutathione S-transferase; 6-OHDA, 6-
hydroxydopamine; NADPH, nicotinamide adenine dinucleotide phosphate-oxidase; SOD, superoxide dismutase
Each value expressed as mean  SD (n ¼ 10 mice/group)
* SOD activity are expressed as (U)/mg protein.
y CAT activity are expressed as (U)/mg protein.
z GR activiy are expressed as nmol NADPHminmg1 protein.
x GPx activity are expressed as nmol NADPHminmg1 protein.
jj GST activity are expressed as nmol CDNB conjugatedminmg1 protein.
{ P < 0.05 when compared 6-OHDA/vehicle or 6-OHDA/hesperidin with sham/vehicle.
# P < 0.05 when compared 6-OHDA/Hesperidin or 6-OHDA/vehicle with sham/vehicle.
** P < 0.05 when compared 6-OHDA/hesperidin with 6-OHDA/vehicle.
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the striatum. Oral administration of hesperidin (50 mg/kg daily)
prevented the 6-OHDA-induced decrease of striatal DA levels
(Table 3).
A two-way ANOVA of DOPAC levels in the striatum de-
monstrated a signiﬁcant 6-OHDA  hesperidin interaction
(F1.40 ¼ 4.15; P ¼ 0.04) and yielded a main effect of 6-OHDA
(F1.40 ¼ 49.43; P ¼ 0.001) (Table 3). Post hoc comparisons
demonstrated that 6-OHDA signiﬁcantly decreased striatal
DOPAC levels, and the daily administration of hesperidin
(50 mg/kg) prevented reductions in DOPAC levels caused by
6-OHDA.
A two-way ANOVA of striatal HVA levels demonstrated a
signiﬁcant 6-OHDA  hesperidin interaction (F1.40 ¼ 3.56;
P ¼ 0.05) and yielded a main effect hesperidin (F1.40 ¼ 5.62;
P ¼ 0.03), as well as 6-OHDA (F1.40 ¼ 39.78; P ¼ 0.001) (Table 3).
Post hoc comparisons demonstrated that 6-OHDA signiﬁcantly
decreased striatal HVA compared with the sham/vehicle group.
Oral administration of hesperidin (50mg/kg daily) prevented the
decrease of striatal HVA levels caused by 6-OHDA.Discussion
This study demonstrated the potential protective effects of
hesperidin against nigrostriatal dopaminergic neuronal toxicity
induced by 6-OHDA injections in aged mice. Injections of
6-OHDA potentiated both the cognitive and depressive deﬁcits
accompanying oxidative damage with the loss of DA and its
levels of metabolites DOPAC and HVA. Oral hesperidin treatment
(50 mg/kg daily) attenuated behavioral alterations and protectedTable 3
Effect of hesperidin on DA, DOPAC, and HVA levels in striatum of mice injected
with 6-OHDA
Groups DA* DOPAC* HVA*
Sham/vehicle 726.6  17.5 40.6  2.1 71.0  3.9
Sham/hesperidin 715.5  36.5 39.9  1.2 72.8  3.3
6-OHDA/vehicle 360.0  24.2y 22.2  1.9y 40.6  4.4y
6-OHDA/hesperidin 508.6  40.7z 29.8  2.4z 56.4  2.8z
DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid;
6-OHDA, 6-hydroxydopamine
Each value expressed as mean  SD (n ¼ 10 mice/group)
* Levels are expressed as ng/g wet weight of striatum.
y P < 0.05 when compared with 6-OHDA/vehicle with sham/vehicle.
z P < 0.05 when compared 6-OHDA/hesperidin with 6-OHDA/vehicle and
sham/vehicle.the striatum of aged mice against oxidative stress, as well as
against reductions of DA and its levels of levels of metabolites
caused by 6-OHDA exposure, probably through its demonstrated
modulation of antioxidant status.
Regarding PD symptoms, an increasing number of studies
have demonstrated that PD seems to be a multidimensional
disease, and in addition to motor deﬁcits, it is associated with a
number of cognitive and depressive disturbances that result in a
loss of quality of life of individuals with PD [34]. Depression is
among the most common psychiatric conditions accompanying
PD. Indeed, depending on the criteria measured, depression can
affect 10% to 45% of patients with PD [35]. Furthermore, it has
been shown that depression may largely precede the onset of
motor symptoms of PD [35,36]. The ﬁndings discussed here
indicated that infusions of the neurotoxin 6-OHDA were able to
produce depressive-like behaviors, as assessed through the TST,
similar to previous reports [37,38]. Alterations in the dopami-
nergic system suggest, therefore, that neurotransmitter systems
play an important role in depressive-like behaviors in the current
model tested, thereby further supporting the involvement of
these neurotransmitter systems in PD-related depression [39].
Our results demonstrated that the 6-OHDA/hesperidin group
demonstrated less immobility time than the 6-OHDA/vehicle
group, showing that ﬂavonoid had antidepressant-like effects in
this model of 6-OHDA-induced PD in mice. Interestingly, we
recently demonstrated that hesperidin treatment is also linked
to the modulation of depression in mice [14,15].
In addition to the emotional deﬁcits presented by patients
with PD, the disease seems to produce cognitive deﬁcits as well,
particularly in procedural memory. The striatum has been the
main area implicated in procedural learning dysfunctions [38,
40], consistent with earlier studies reporting that PD models
impair mouse performance in cognitive tests [41,42]. Therefore,
we investigated putative spatial memory dysfunction in mice
after 6-OHDA injections by using the Morris water maze task.
Mice injected with 6-OHDA did not differ from the control group
in their escape latencies for ﬁnding the platform, and all exper-
imental groups were able to learn the task during training. Our
data demonstrated that 6-OHDA injections induced long-term
memory impairment in the 6-OHDA/vehicle group, as revealed
by the reduction of percent of time spent in the correct quadrant
in the Morris water maze task. This effect was revealed by the
reduction of the percent of time spent in the correct quadrant in
the Morris water maze task. It is important to emphasize that
these treatments have not caused sedative effect or excitement
in animals as shown in the OFT. Importantly, the percentages of
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oxidative stress observed in this study, were similar to previous
studies showing deﬁcits in memory tasks [41,43]. As for the
cognitive deﬁcits found in this test, our ﬁndings support the
hypothesized involvement of striatal DA ant its levels of me-
tabolites and antioxidant deﬁcits induced by 6-OHDA in memory
in this model of PD. In our study, hesperidin treatment at the
dose of 50 mg/kg protected against cognitive impairment
induced by 6-OHDA and preserved the spatial memory with
mechanisms such as antioxidant and DA enhancement.
6-OHDA is a selective catecholamine neurotoxin and could
easily undergo autoxidation to yield hydrogen peroxide and
superoxide radicals, which then take part in a secondary metal-
catalyzed Haber-Weiss reaction that produces hydroxyl free
radicals [44]. In this study, 6-OHDA infusion caused an over-
production of free radicals that, in turn, caused oxidative
damage to membrane lipids and protein levels, ultimately
leading to a modiﬁcation in the activity of antioxidant enzymes.
This oxidative neuronal damage in 6-OHDA-treated rodents is
consistent with previous reports [10,45]. As a result, the vehicle
group of mice exposed to 6-OHDA exhibited inhibition of GPx
and CAT activity and increases in GR and SOD. Additionally, our
data conﬁrms that the tested toxin initiated an oxidative
cascade of events in the striatum, through the formation of ROS,
and decreased levels of GSH and TRAP. The increase of SOD and
GR activities it is suggested that as adaptive mechanism to
compensate for increased RS levels, as well as decreased levels
of GSH and TRAP. To meet this rise, increased SOD activity as a
counterbalance mechanism, resulting in a large production of
H2O2. Although the hesperidin treatment did not modify SOD
activity, it may have acted directly on O2– and also modulated
the activities of CAT, GPx, and GR in the absence of a decrease
in H2O2 levels. Thus the protective effect of hesperidin may be
due to its action against oxidative stress, brought on by O2–,
and the modulation of the antioxidant enzymes with the
exception of SOD. The increase in GR activity in the
6-OHDA/hesperidin group indicates hesperidin acts to maintain
antioxidant defenses in part by maintaining GSH levels. In
agreement with these data, previous studies have reported
increased GR activity in different encephalic structures after
prooxidative insults [46,47]. This work is in accordance with
previous results [23,48] in studies on other neurodegenerative
diseases. Indeed, across different biological systems, hesperidin
has been demonstrated to act as an antioxidant that stabilizes
biomembranes and thus prevents cell membrane damage in
other neurodegenerative diseases, such as Alzheimer’s and
Huntington’s [16,18].
The measurement of monoamine neurotransmitters in the
basal ganglia serves as an important method to determine
whether a particular drug has a therapeutic effect on dopa-
minergic neurons. The activities of dopaminergic neurons can
thus be inferred by determining the DA, DOPAC, and HVA
levels in the brain or in the cerebrospinal ﬂuid [6]. To this end,
we performed high-pressure liquid chromatography with
electrochemical detection (HPLC ECD) to detect striatal
monoamine neurotransmitters, and we found that DA, DOPAC,
and HVA levels were signiﬁcantly decreased following 6-OHDA
exposure, which is similar to previous reports [9,10,49,50]. We
can infer from the this study that oral administration of hes-
peridin (50 mg/kg) daily for 4 wk may attenuate the
6-OHDA-induced catecholamine neurotoxicity, thereby main-
taining the concentration of DA and its levels of metabolites at
normal or close to normal levels. Therefore, in this PD model
induced by 6-OHDA, hesperidin appears to act via antioxidantand DA-enhancing mechanisms that rescue the compromised
cells in striatum.
The present study demonstrated that treatment with hes-
peridin (50 mg/kg) daily for 28 d was effective in attenuating the
following impairments resulting from 6-OHDA exposure inmice:
1. depressive-like behavior inferred from TST;
2. impairment of cognitive performance based on the Morris
water maze task;
3. increased ROS levels;
4. decreased GSH levels and TRAP;
5. inhibition of GPx and CATactivity and rises in GR activity; and
6. decreased DA, DOPAC and HVA levels.
In view of our results, we have provided the ﬁrst data indi-
cating that hesperidin acts as a protective agent through the
analysis of behavioral, neurochemical, and biochemical param-
eters in aging mice submitted to an experimental model of PD
induced by 6-OHDA. These results provide new insights into
experimental models of PD, indicating that hesperidin may
represent a new therapeutic tool for the treatment of PD.
Conversely, further research is needed to clarify the precise
molecular mechanisms involved in the protective effects induced
by hesperidin in the 6-OHDA model of PD.
Conclusion
This study demonstrated a protective effect of hesperidin on
the neurotoxicity induced by 6-OHDA in aged mice, increasing
the DA levels, enzymatic, and non-enzymatic activity, decreasing
the ROS and improving the behavioral parameters. To our
knowledge, we have provided the ﬁrst set of preclinical data
indicating that hesperidin could be useful as a therapy for the
treatment of PD.
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